Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-13 7:06 pm Purchase | 2025-09-30 | 13G | NewAmsterdam Pharma Company N.V. NAMS | Capital World Investors | 9,822,711 8.700% | 1,434,986 (+17.11%) | Filing History |
| 2025-11-07 7:19 pm Purchase | 2025-11-05 | 13D | NewAmsterdam Pharma Company N.V. NAMS | BCLS II Investco, LP | 11,422,504 9.990% | 703,394 (+6.56%) | Filing History |
| 2025-11-04 5:23 pm Purchase | 2025-11-01 | 13D | NewAmsterdam Pharma Company N.V. NAMS | Frazier Life Sciences X, L.P. | 8,623,939 7.700% | 1,296,002 (+17.69%) | Filing History |
| 2025-09-30 4:47 pm Sale | 2025-09-26 | 13D | NewAmsterdam Pharma Company N.V. NAMS | Forbion Capital Fund IV Cooperatief U.A. | 9,316,914 8.300% | -1,261,892 (-11.93%) | Filing History |
| 2025-08-20 5:28 pm Sale | 2025-08-18 | 13D | NewAmsterdam Pharma Company N.V. NAMS | Frazier Life Sciences X, L.P. | 7,327,937 6.500% | -9,088,814 (-55.36%) | Filing History |
| 2025-08-13 12:56 pm Purchase | 2025-06-30 | 13G | NewAmsterdam Pharma Company N.V. NAMS | Capital World Investors | 8,387,725 7.500% | 1,589,127 (+23.37%) | Filing History |
| 2025-08-12 4:30 pm Sale | 2025-08-08 | 13D | NewAmsterdam Pharma Company N.V. NAMS | Forbion Capital Fund IV Cooperatief U.A. | 10,578,806 9.400% | -544,808 (-4.90%) | Filing History |
| 2025-05-15 4:58 pm Purchase | 2025-03-31 | 13G | NewAmsterdam Pharma Company N.V. NAMS | RA Capital Management, L.P. | 11,063,125 9.900% | 187,671 (+1.73%) | Filing History |
| 2025-05-13 11:44 am Purchase | 2025-03-31 | 13G | NewAmsterdam Pharma Company N.V. NAMS | Capital World Investors | 6,798,598 6.200% | 6,798,598 (New Position) | Filing History |
| 2025-02-14 6:42 pm Purchase | 2024-12-31 | 13G | NewAmsterdam Pharma Company N.V. NAMS | RA Capital Management, L.P. | 10,875,454 9.900% | 1,779,865 (+19.57%) | Filing History |
| 2025-02-14 4:50 pm Sale | 2024-12-31 | 13G | NewAmsterdam Pharma Company N.V. NAMS | VIKING GLOBAL INVESTORS LP | 6,978,534 6.500% | -1,046,031 (-13.04%) | Filing History |
| 2024-12-17 5:35 pm Purchase | 2024-12-13 | 13D | NewAmsterdam Pharma Company N.V. NAMS | BCLS II Investco, LP | 10,719,110 13.000% | 5,342,754 (+99.38%) | Filing History |
| 2024-12-17 4:00 pm Sale | 2024-12-13 | 13D | NewAmsterdam Pharma Company N.V. NAMS | Forbion Capital Fund IV Cooperatief U.A. | 11,123,614 10.400% | -696,949 (-5.90%) | Filing History |
| 2024-12-17 10:28 am Purchase | 2024-12-13 | 13D | NewAmsterdam Pharma Company N.V. NAMS | Frazier Life Sciences X, L.P. | 16,416,751 15.300% | 3,784,713 (+29.96%) | Filing History |
| 2024-11-15 4:29 pm Sale | 2024-11-13 | 13D | NewAmsterdam Pharma Company N.V. NAMS | Forbion Capital Fund IV Cooperatief U.A. | 11,820,563 12.800% | -10,898 (-0.09%) | Filing History |
| 2024-11-14 5:46 pm Purchase | 2024-09-30 | 13G | NewAmsterdam Pharma Company N.V. NAMS | RA Capital Management, L.P. | 9,095,589 9.990% | 898,256 (+10.96%) | Filing History |
| 2024-08-23 4:20 pm Sale | 2024-08-22 | 13G | NewAmsterdam Pharma Company N.V. NAMS | AMGEN INC AMGN | 0 0.000% | -4,910,000 (Position Closed) | Filing History |
| 2024-03-01 4:30 pm Unchanged | 2024-02-28 | 13D | NewAmsterdam Pharma Company N.V. NAMS | BCLS II Investco, LP | 5,376,356 6.000% | 0 (Unchanged) | Filing History |
| 2024-02-21 11:11 am Purchase | 2024-02-16 | 13D | NewAmsterdam Pharma Company N.V. NAMS | Frazier Life Sciences X, L.P. | 12,632,038 14.200% | 1,485,807 (+13.33%) | Filing History |
| 2024-02-14 5:01 pm Sale | 2024-02-14 | 13G | NewAmsterdam Pharma Company N.V. NAMS | RA Capital Management, L.P. | 8,197,333 9.900% | -1,136,000 (-12.17%) | Filing History |